Effect of breviscapine on fractalkine expression in chronic hypoxic rats

• Published in: Chinese medical journal Vol. 119; no. 17; pp. 1465 - 1468
• Main Authors: Chen, Xiao-ju, Cheng, De-yun, Yang, Li, Xia, Xiu-qiong, Guan, Jian
• Format: Journal Article
• Language: English
• Published: China Department of Respiratory Medicine, West China Hospital,Sichuan University, Chengdu 610041, China 05.09.2006
• Subjects: Animals; Arterioles - metabolism; Arterioles - pathology; Blood Pressure - drug effects; Chemokine CX3CL1; Chemokines, CX3C - analysis; Chemokines, CX3C - genetics; Chronic Disease; Flavonoids - pharmacology; Hypertension, Pulmonary - prevention & control; Hypertrophy, Right Ventricular - prevention & control; Hypoxia - complications; Hypoxia - metabolism; Lung - metabolism; Male; Membrane Proteins - analysis; Membrane Proteins - genetics; Pulmonary Artery - metabolism; Pulmonary Artery - pathology; Rats; Rats, Sprague-Dawley; RNA, Messenger - analysis; 慢性组织缺氧; 肺疾病; 高血压; hypoxia; breviscapine; fractalkine; pulmonary hypertension
• ISSN: 0366-6999; 2542-5641
• DOI: 10.1097/00029330-200609010-00010

Fractalkine （FKN） is the only known chemokine that fulfils the dual functions of an adhesive molecule and a soluble chemoattractant.1 FKN expression was reported increase in lungs of patients with severe pulmonary arterial hypertension,2 suggesting that FKN may participate in pathogenesis of pulmonary hypertension. Breviscapine is a flavonoid extracted from Erigeron breviscapus （Vant.） Hand. Mazz. Breviscapine can prevent the development of hypoxic pulmonary hypertension^3 but the mechanism is unknown. This study evaluated the role of FKN in the pathogenesis of hypoxic pulmonary hypertension and the effect of breviscapine on FKN in hypoxic pulmonary hypertension.